drug · vaccine component
SurVaxM
Phase 2updated 6mo agoby MimiVax LLC🔗 ChEMBL
Phase 2community read0 votes
Vaccine component drug with a maximum clinical stage of Phase 2 (across all indications), with 4 investigational indications.
targets
Baculoviral IAP repeat-containing protein 5Hemocyanin 1
all catalysts(0)
nothing on the calendar yet
Trials studying SurVaxM
News(3)
- MimiVax’s cancer vaccine fails phase 2 glioblastoma study, but CEO still sees data as ‘inspiring’MimiVax has reports a phase 2b miss in newly diagnosed glioblastoma patients, but remains positive about a significant survival benefit in a subset of patients 65 years and under.fiercebiotech · 1mo ago
- GU Cancer Experts Highlight Top Abstracts to Watch During ASCO 2026We spoke with leading voices in GU oncology to see which presentations they are most looking forward to during the 2026 ASCO Annual Meeting.onclive · 6mo ago
- MimiVax and Roswell Park Open Phase 2 Trial of SurVaxM for Patients with Metastatic Neuroendocrine TumorsRoswell Park Comprehensive Cancer Center launched a phase 2 trial evaluating SurVaxM plus temozolomide in progressing neuroendocrine tumors.onclive · 6mo ago
Data sources
last refreshed 4h ago
Found something off?
comments(0)
5-min edit window · permanent after that